{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Fpbc-data-from-aasld-part-3-_zso_FYw","width":444,"version":"1.0","type":"rich","title":"Selected FXR Agonist PBC Studies: Conference Coverage of AASLD","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/1542e4f0-fb77-4a43-9710-6efdd57fda82/pbc-aasld-cf-prp6225-pod734-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/b5bb37ba-18aa-449f-b845-55959ac42cdf\" height=\"200\" width=\"100%\" title=\"Selected FXR Agonist PBC Studies: Conference Coverage of AASLD\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen as Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses exciting new data from AASLD 2023 for people with PBC, including a study that evaluated real-world outcomes in patients treated with an FXR agonist as second-line therapy, lessons learned from PBC outcomes trials, and a late-breaking study of PBC treatment using an FXR agonist plus a fibrate."}